Thomas Burns - Glaukos Corp Chairman
| GKOS Stock | USD 102.26 1.63 1.62% |
Chairman
Mr. Thomas W. Burns is President, Chief Executive Officer and Director of Glaukos Corporationrationration. Mr. Burns has also been a member of the board of directors of DOSE Medical Corporationrationration, serving as its chairman of the board, since October 2009 and served as its chief executive officer and president from March 2010 until June 2015. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, surgical products and overthecounter products. Prior to joining our Company, Mr. Burns led Eyetech Pharmaceuticals, Inc. as its president and chief operating officer, and as a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation, and then as vice president, global strategy and general manager, refractive surgery, of Bausch Lomb from 1998 to 2000. Mr. Burns has also served as an entrepreneur in residence at Versant Ventures Management, LLC. Mr. Burns received a B.A. from Yale University. Mr. Burns currently serves as a director and as the chair of the compensation committee on the board of Avedro, Inc. .agreement terminated in its entirety upon the closing of our initial public offering. since 2022.
| Age | 64 |
| Tenure | 3 years |
| Address | One Glaukos Way, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Thomas Burns Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Burns against Glaukos Corp stock is an integral part of due diligence when investing in Glaukos Corp. Thomas Burns insider activity provides valuable insight into whether Glaukos Corp is net buyers or sellers over its current business cycle. Note, Glaukos Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Glaukos Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Burns over a month ago Disposition of 529 shares by Thomas Burns of Glaukos Corp at 93.57 subject to Rule 16b-3 | ||
Thomas Burns over two months ago Disposition of 529 shares by Thomas Burns of Glaukos Corp at 92.69 subject to Rule 16b-3 | ||
Thomas Burns over two months ago Disposition of 4059 shares by Thomas Burns of Glaukos Corp at 138.93 subject to Rule 16b-3 | ||
Thomas Burns over six months ago Acquisition by Thomas Burns of 16832 shares of Glaukos Corp at 55.18 subject to Rule 16b-3 |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0706) % which means that it has lost $0.0706 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2383) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2025. Return On Capital Employed is likely to drop to -0.14 in 2025. At this time, Glaukos Corp's Non Currrent Assets Other are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 640 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 287.1 M in 2025.Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Bill Sanford | Integer Holdings Corp | 76 | |
| William Kozy | LivaNova PLC | 72 | |
| Frank Laukien | Bruker | 65 | |
| DKeith Grossman | Nevro Corp | 64 | |
| Curt Hartman | CONMED | 61 | |
| Mark Tryniski | CONMED | 60 | |
| D Grossman | Nevro Corp | 59 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0706 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilbert Kliman, Independent Director | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Diane Biagianti, Sr Counsel | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Aimee Weisner, Independent Director | ||
| Mory Gharib, CoFounder | ||
| Michele Allegretto, Senior Resources | ||
| Robert Davis, General VP | ||
| David Hoffmeister, Independent Director | ||
| Denice Torres, Independent Director | ||
| Tracy Founds, Senior Safety | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Tomas Navratil, Chief Development Officer | ||
| MD FACS, Chief Officer | ||
| Jane Rady, Senior Development | ||
| Robert JD, General VP | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0706 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 5.48 B | ||||
| Shares Outstanding | 56.57 M | ||||
| Shares Owned By Insiders | 3.32 % | ||||
| Shares Owned By Institutions | 96.84 % | ||||
| Number Of Shares Shorted | 3.54 M | ||||
| Price To Earning | 94.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.